This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Maes, L. Articles by Vanden Berghe, D. Search for Related Content PubMed PubMed Citation Articles by Maes, L. Articles by Vanden Berghe, D.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2004, p. 2056-2060, Vol. 48, No. 6
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.6.2056-2060.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Comparative Activities of the Triterpene Saponin Maesabalide III and Liposomal Amphotericin B (AmBisome) against Leishmania donovani in Hamsters

Louis Maes,^1* Nils Germonprez,² Ludo Quirijnen,³ Luc Van Puyvelde,² Paul Cos,¹ and Dirk Vanden Berghe¹

Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Wilrijk,¹ Tibotec bvba., Mechelen, Belgium,³ National Center for Natural Sciences and Technology, Cau Giay District, Hanoi, Vietnam²

Received 13 November 2003/ Returned for modification 22 December 2003/ Accepted 30 January 2004

Maesabalide III (MB-III), an oleane triterpene saponin isolated from the Vietnamese plant Maesa balansae, is a new antileishmanial lead compound whose activity against Leishmania donovani (MHOM/ET/67/L82) in groups of five golden hamsters was evaluated after administration of a single subcutaneous dose on either day 1 (prophylactic treatment) or day 28 (curative treatment) after infection. Liposomal amphotericin B (AmBisome), administered intravenously at 5 mg/kg of body weight, was used as the reference drug. Amastigote burdens in liver, spleen, and bone marrow were determined either 7 days (early effects) or 56 days (late effects) after treatment. Prophylactic administration of MB-III at 0.2 mg/kg reduced liver amastigote burdens by 99.8 and 83% within 7 and 56 days after treatment, respectively. In the latter group, however, all animals became ill and some died. Both MB-III at 0.8 mg/kg and liposomal amphotericin B were 100% effective against liver stages, but clearance from the spleen and bone marrow was not achieved. Curative administration of MB-III at 0.2 and 0.4 mg/kg was not protective, as no survivors were left at the termination of the experiment on day 84. Despite the high level of reduction of the liver amastigote burden after treatment with MB-III at 0.8 mg/kg (94.2%) or liposomal amphotericin B (99.4%), clinical protection could not be obtained in either group, with two deaths occurring and the residual liver burdens persisting. It is concluded that administration of a single dose of MB-III at 0.8 mg/kg has efficacy potential comparable to that of a single dose of liposomal amphotericin B at 5 mg/kg and is therefore considered a promising new antileishmanial lead compound. However, multiple-dose pharmacological, toxicological, and pharmacokinetic studies are still needed before it can become a valid drug candidate for development.

---

* Corresponding author. Mailing address: Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, Antwerp University, Groenenborgerlaan 171-V523, B-2610 Wilrijk, Belgium. Phone: (32) 3.265.33.54. Fax: (32) 3.280.25.44. E-mail: louis.maes{at}ua.ac.be.

---

Antimicrobial Agents and Chemotherapy, June 2004, p. 2056-2060, Vol. 48, No. 6
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.6.2056-2060.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.